Influence of body mass index on survival in veterans with multiple myeloma

Oncologist

Volumn 18, Issue 10, 2013, Pages 1074-1079

  Beason, Tracey S ^a,b   Chang, Su Hsin ^a   Sanfilippo, Kristen M ^a,b   Luo, Suhong ^b   Colditz, Graham A ^a   Vij, Ravi ^a   Tomasson, Michael H ^a   Dipersio, John F ^a   Stockerl Goldstein, Keith ^a   Ganti, Arun ^b   Wildes, Tanya ^a   Carson, Kenneth R ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Body mass index; Mortality; Multiple myeloma; Obesity; Overweight; Survival

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; DISEASE CLASSIFICATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; OBESITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; VERY ELDERLY; VETERAN; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OBESITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; VETERANS; WEIGHT LOSS;

EID: 84886045468     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0015     Document Type: Article

References (33)

1. Flegal KM, Carroll MD, Ogden CL et al. Prevalence and trends in obesityamong US adults, 1999-2010. JAMA 2010;303:235-241.
2. Hill AL, Rand DG, NowakMAet al. Infectious disease modeling of social contagion in networks. PLoS Comput Biol 2010;6:e1000968.
3. Adams KF, Schatzkin A, Harris TB et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006;355:763-778.
4. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.
5. Lichtman MA. Obesity and the risk for a hematological malignancy: Leukemia, lymphoma, or myeloma. The Oncologist 2010;15:1083-1101.
6. Estey E, Thall P, KantarjianHet al. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 1997;11:1661-1664.
7. WongO, Harris F, WangY et al. Ahospital-based case-control study of non-Hodgkin lymphoid neoplasms in Shanghai: Analysis of personal characteristics, lifestyle, and environmental risk factors by subtypes of theWHOclassification. J Occup Environ Med 2010;52:39-53.
8. Breccia M, Mazzarella L, Bagnardi V et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocyticleukemiatreated with the AIDA protocols. Blood 2012;119:49-54.
9. Larsson SC, WolkA, LarssonSCet al. Obesityand risk of non-Hodgkin's lymphoma: A meta-analysis. Int J Cancer 2007;121:1564-1570.
10. Carson KR, Barlett NL, McDonald JR et al. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol 2012;30: 3217-3222.
11. Wallin A, Larsson S. Body mass index and the risk of multiple myeloma: A meta-analysis of prospective studies. Eur J Cancer 2011;47:1606-1615.
12. Reeves GK, Pirie K, Beral V et al. Million Women Study Collaboration. Cancer incidence and mortality in relation to body mass index in the Million Women Study: Cohort study. BMJ2007;335:1134.
13. Chiu BC, Gapstur SM, Greenland P et al. Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2348-2354.
14. KhanMM, MoriM, SakauchiFet al. Risk factors for myeloma: Evidence from the Japan Collaborative Cohort (JACC) study. Asian Pac J Cancer Prev 2006;7:575-581.
15. Parr C, Batty GD, Lam TH et al. Body-mass index and cancer mortality in the Asian-Pacific Cohort Studies Collaboration: Pooled analyses of 424,519 participants. Lancet Oncol 2010;11:741-752.
16. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 1993;46:1075-1079; discussion 1081-1090.
17. Savas LS, del Junco DJ, Bastian LA et al. Mortality ascertainment of women veterans: A comparison of sources of vital status information, 1979-2010 Med Care 2009;47:125-128.
18. Sohn MW, Arnold N, Maynard C et al. Accuracy and completeness of mortality data in the DepartmentofVeteransAffairs. PopulHealthMetr2006;4:2.
19. Global database on body mass index. Avalable at http://apps.who.int/bmi/index.jsp?introPage_ intro_3.htm. Accessed April 27, 2012.
20. Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
21. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's LymphomaPrognostic Factors Project. NEngl JMed 1993;329:987-994.
22. Ng AK, Bernardo MP, Weller E et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated atage50 or younger. J Clin Oncol 2002;20:2101-2108.
23. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32.
24. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36:842-854.
25. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
26. Salles G, Bienvenu J, Bastion Y et al. Elevated circulating levels of TNFalpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Br J Haematol 1996;93:352-359.
27. Rathore VB, Advani SH, Nadkarni JJ. Altered release of tumor necrosis factor and its soluble receptor in non-Hodgkin's lymphoma patients. Cancer Detect Prev 1999;23:226-231.
28. SeymourJF, TalpazM, Cabanillas F et al. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995;13: 575-582.
29. Bataille R, Boccadoro M, Klein B et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80:733-737.
30. Cahlin C, Korner A, Axelsson H et al. Experimentalcancer cachexia:Therole of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia Cancer Res 2000;60:5488-5493.
31. Durie BG, Kyle RA, BelchAet al. Myelomamanagement guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003;4:379-398.
32. Fonseca R, Blood E, RueMet al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569-4575.
33. Perry AM, Cardesa-Salzmann TM, Meyer PN et al. A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood;120:2290-2296.